학술논문

Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.
Document Type
Article
Source
Clinical Infectious Diseases. 12/1/2016, Vol. 63 Issue 11, p1463-1469. 7p.
Subject
*INVASIVE candidiasis
*ANTIFUNGAL agents
*INTENSIVE care units
*ROUTINE diagnostic tests
*HOSPITAL admission & discharge
*THERAPEUTICS
Language
ISSN
1058-4838
Abstract
Background. Delayed antifungal therapy for invasive candidiasis (IC) contributes to poor outcomes. Predictive risk models may allow targeted antifungal prophylaxis to those at greatest risk. Methods. A prospective cohort study of 6685 consecutive nonneutropenic patients admitted to 7 Australian intensive care units (ICUs) for ⩾72 hours was performed. Clinical risk factors for IC occurring prior to and following ICU admission, colonization with Candida species on surveillance cultures from 3 sites assessed twice weekly, and the occurrence of IC ⩾72 hours following ICU admission or ⩽72 hours following ICU discharge were measured. From these parameters, a risk-predictive model for the development of ICU-acquired IC was then derived. Results. Ninety-six patients (1.43%) developed ICU-acquired IC. A simple summation risk-predictive model using the 10 independently significant variables associated with IC demonstrated overall moderate accuracy (area under the receiver operating characteristic curve = 0.82). No single threshold score could categorize patients into clinically useful high- and low-risk groups. However, using 2 threshold scores, 3 patient cohorts could be identified: those at high risk (score ⩾6, 4.8% of total cohort, positive predictive value [PPV] 11.7%), those at low risk (score ⩽2, 43.1% of total cohort, PPV 0.24%), and those at intermediate risk (score 3-5, 52.1% of total cohort, PPV 1.46%). Conclusions. Dichotomization of ICU patients into high- and low-risk groups for IC risk is problematic. Categorizing patients into high-, intermediate-, and low-risk groupsmay more efficiently target early antifungal strategies and utilization of newer diagnostic tests. [ABSTRACT FROM AUTHOR]